"The U.S. Food and Drug Administration is alerting health care providers and patients of a voluntary nationwide recall of all lots of Omontys Injection by Affymax, Inc., of Palo Alto, Calif., and Takeda Pharmaceuticals Company Limited, of Deerfiel"...
The expected manifestations of PROCRIT® (epoetin alfa) overdosage include signs and symptoms associated with an excessive and/or rapid increase in hemoglobin concentration, including any of the cardiovascular events described in WARNINGS and listed in ADVERSE REACTIONS. Patients receiving an overdosage of PROCRIT® (epoetin alfa) should be monitored closely for cardiovascular events and hematologic abnormalities. Polycythemia should be managed acutely with phlebotomy, as clinically indicated. Following resolution of the effects due to PROCRIT® (epoetin alfa) overdosage, reintroduction of PROCRIT® (epoetin alfa) therapy should be accompanied by close monitoring for evidence of rapid increases in hemoglobin concentration ( > 1 gm/dL per 14 days). In patients with an excessive hematopoietic response, reduce the PROCRIT® (epoetin alfa) dose in accordance with the recommendations described in DOSAGE AND ADMINISTRATION.
PROCRIT® (epoetin alfa) is contraindicated in patients with:
- Uncontrolled hypertension.
- Known hypersensitivity to mammalian cell-derived products.
- Known hypersensitivity to Albumin (Human).
Last reviewed on RxList: 6/20/2012
This monograph has been modified to include the generic and brand name in many instances.
Additional Procrit Information
Procrit - User Reviews
Procrit User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.